All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YF446 | Anti-VEGF×Ang2 (Bevacizumab×L1-10) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF447 | Anti-VEGF×Ang2 (Bevacizumab×ANG2-1) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF448 | Anti-VEGF×Ang2 (B20×LC06) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | B20 | Human | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF450 | Anti-VEGF×Ang2 (Bevacizumab×LC08) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF451 | Anti-VEGF×Ang2 (Bevacizumab×LC10) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF452 | Anti-VEGF×Ang2 (Bevacizumab×LC06 (E6Q)) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF493 | Anti-VEGF×Ang2 (Bevacizumab×L1-10) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF494 | Anti-VEGF×Ang2 (Bevacizumab×ANG2-1) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF495 | Anti-VEGF×Ang2 (B20×LC06) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | B20 | Human | scFv (VEGF)-scFv (Ang2)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF497 | Anti-VEGF×Ang2 (Bevacizumab×LC08) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF540 | Anti-VEGF×Ang2 (Bevacizumab×L1-10) h(CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF541 | Anti-VEGF×Ang2 (Bevacizumab×ANG2-1) h(CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF542 | Anti-VEGF×Ang2 (B20×LC06) h(CD3ζ) TanCAR, pCDCAR1 | Human | B20 | Human | scFv (VEGF)-scFv (Ang2)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF544 | Anti-VEGF×Ang2 (Bevacizumab×LC08) h(CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF545 | Anti-VEGF×Ang2 (Bevacizumab×LC10) h(CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF591 | Anti-VEGF×Ang2 (Bevacizumab×LC08) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF592 | Anti-VEGF×Ang2 (Bevacizumab×LC10) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF593 | Anti-VEGF×Ang2 (Bevacizumab×LC06 (E6Q)) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF634 | Anti-VEGF×Ang2 (Bevacizumab×L1-10) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF635 | Anti-VEGF×Ang2 (Bevacizumab×ANG2-1) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Bevacizumab | Humanized | scFv (VEGF)-scFv (Ang2)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION